

compounds. In fact, the cited references do not disclose or suggest compounds having a pyridyl ring substituted both at the 5 position with a non-hydrogen substituent and at the 3 position with a pentene substituent having an amine substituent at its 2 position. For at least the foregoing reasons, Applicants respectfully submit that new Claims 21-27 are patentable over the cited references.

II. Co-pending Applications

Applicants direct the Examiner's attention to the following co-pending applications:

U.S. Serial No. 08/804,248, entitled *Pharmaceutical Compositions Incorporating Aryl Substituted Olefinic Amine Compounds*.

U.S. Serial No. 09/642,351, entitled *Pharmaceutical Compositions for Prevention and Treatment of Central Nervous System Disorders*, which is a continuation application of U.S. Serial No. 09/631,761 cited in the Information Disclosure Statement dated March 9, 2000.

U.S. Serial No. 09/098,285, entitled *Compounds Capable of Activating Cholinergic Receptors*, which is the parent of the present application.

U.S. Serial No. 09/641,496, entitled *Compounds Capable of Activating Cholinergic Receptors*, which is a second continuation application of parent application U.S. Serial No. 09/098,285.

U.S. Serial No. 09/098,133, entitled *Pharmaceutical Compositions and Methods for Use*, which was inadvertently identified as U.S. Serial No. 09/093,133 in the Information Disclosure Statement dated March 9, 2000.

U.S. Serial No. 09/295,181, entitled *Pharmaceutical Compositions for Inhibition of Cytokine Production and Secretion*.

U.S. Serial No. 09/656,284, entitled *Pharmaceutical Compositions for Inhibition of Cytokine Production and Secretion*, which is a divisional application of U.S. Serial No. 09/295,181.

U.S. Serial No. 09/327,141, entitled *Pharmaceutical Compositions and Methods for Use*.

In re: Caldwell et al.
Serial No.: 09/522,117
Filed: March 9, 2000
Page 4

U.S. Serial No. 09/570,226, entitled *Pharmaceutical Compositions and Methods for Use*, which is a continuation application of U.S. Serial No. 09/327,141.

U.S. Serial No. 09/327,774, entitled *Pharmaceutical Compositions and Methods for Use*, which is a continuation-in-part application of U.S. Serial No. 09/098,133 cited in the Information Disclosure Statement date March 9, 2000.

U.S. Serial No. 09/431,700, entitled *Pharmaceutical Compositions and Methods for Use*.

U.S. Serial No. 09/562,485, entitled *Imaging of Nicotinic Acetylcholine Receptor Subtypes*.

U.S. Serial No. 09/616,743, entitled *Pharmaceutical Compositions and Methods for Use*.

U.S. Serial No. 09/616,187, entitled *Pharmaceutical Compositions and Method for Use*.

U.S. Serial No. 09/317,327, entitled *Pharmaceutical Compositions and Methods for Use*.


U.S. Serial No. 09/327,149, entitled *Pharmaceutical Compositions and Methods for Use*.

U.S. Serial No. 09/387,149, entitled *Pharmaceutical Compositions and Methods for Use*.

III. Conclusion

The concerns of the Examiner addressed in full, Applicants respectfully request the issuance of a Notice of Allowance.

Respectfully submitted,



J. Michael Strickland
Registration No. 47,115
Attorney for Applicant(s)